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ABSTRACT
The lack of standardized criteria for quantitative measurement of therapeutic response in clinical trials poses
a major obstacle for the development of new agents in chronic graft-versus-host disease (GVHD). This
consensus document was developed to address several objectives for response criteria to be used in chronic
GVHD-related clinical trials. The proposed measures should be practical for use both by transplantation and
nontransplantation medical providers, adaptable for use in adults and in children, and focused on the most
important chronic GVHD manifestations. The measures should also give preference to quantitative, rather
than semiquantitative, measures; capture information regarding signs, symptoms, and function separately from
each other; and use validated scales whenever possible to demonstrate improved patient outcomes and meet
requirements for regulatory approval of novel agents. Based on these criteria, we propose a set of measures to
be considered for use in clinical trials, and forms for data collection are provided (http://www.asbmt.org/
GvHDForms). Measures should be made at 3-month intervals and whenever major changes are made in
treatment. Provisional definitions of complete response, partial response, and progression are proposed for
each organ and for overall outcomes. The proposed response criteria are based on current expert consensus
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Response Criteria in Chronic GVDH
Bopinion and are intended to improve consistency in the conduct and reporting of chronic GVHD trials, but
their use remains to be demonstrated in practice.
© 2006 American Society for Blood and Marrow Transplantation
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2NTRODUCTION
Overall survival or survival to permanent resolu-
ion of chronic graft-versus-host disease (GVHD) and
iscontinuation of systemic immunosuppression are
ong-term clinical outcomes that are accepted major
nd points in chronic GVHD clinical trials [1-3], but
hese long-term outcomes are not suitable for early-
hase studies. Qualitative assessments of chronic
VHD manifestations can guide clinical decisions but
re not adequate for measuring outcomes in clinical
rials. To accelerate development of novel therapeutic
gents in chronic GVHD, quantitative research tools
re needed to measure short-term responses to treat-
ent and to predict long-term clinical beneﬁt.
The lack of standardized quantitative response cri-
eria poses one of the major obstacles in pursuing
herapeutic trials for chronic GVHD [4]. No gener-
lly accepted, much less validated, quantitative criteria
or organ-speciﬁc or overall responses have been de-
eloped previously. The deﬁnitions of response typi-
ally used in previous studies have been global and
ualitative in nature, with considerable variability
rom one study to the next (extensively reviewed by
orgun Akpek in Attachment 1 at http://www.asbmt.
rg/GvHDForms). In addition, methods have not
een developed to account for the distinction between
eversible disease activity and irreversible damage.
Because no currently available database has infor-
ation from patients with chronic GVHD at a sufﬁ-
ient level of detail, retrospective methods could not
e used to identify clinical characteristics that are
ensitive to change and predictive for major outcomes.
he Working Group began by reviewing instruments
urrently used by hematopoietic stem cell transplan-
ation physicians at Johns Hopkins, Children’s Oncol-
gy Group, Fred Hutchinson Cancer Research Cen-
er, Harvard University, University of Minnesota, and
ational Institutes of Health. The Working Group
lso included specialists from other ﬁelds, including
heumatology and gastroenterology, to beneﬁt from
heir experiences in developing and using chronic dis-
ase activity indices and response criteria in clinical
rials [5-8].
This document is based on a broad consensus of
xperts and on the use of the best available data. These
005 recommendations are intended to advance stan-
ards of chronic GVHD therapeutic trials, but they
emain provisional and will need to be validated and
B&MTeﬁned according to data emerging from prospective
tudies. The Working Group could not entirely re-
olve certain intrinsic tensions between divergent
oals. On the one hand, the assessments should be as
imple as possible to facilitate their use by clinicians
utside the ﬁeld of hematopoietic cell transplantation,
ut on the other hand, the assessments should contain
s much information as possible to support research.
he former goal would require immediate item re-
uction and enforcement of consistency based on ex-
ert opinion, whereas the latter goal would encourage
urther exploration, with deferral of item reduction
ntil data are available. For certain organs, the Work-
ng Group could not identify quantitative measures
hat would be suitable for use in clinical trials, even
hough qualitative assessments can be used for clinical
anagement. In the end, the Working Group pro-
osed a broad set of assessment measures that should
e feasible in most academic settings, although some
impliﬁcation might be needed if the assessments are
o be used by medical providers outside the ﬁeld of
ematopoietic cell transplantation.
The differences between this document and the
iagnosis and Staging document should be noted [9].
lthough there is appearance of some overlap, char-
cteristics that could help establish the diagnosis of
hronic GVHD or to assess the severity of chronic
VHD at a single time point might not serve as the
ost appropriate or sensitive measures for chronic
VHD disease activity. Conversely, a sensitive mea-
ure of chronic GVHD response might not necessarily
erve as an appropriate diagnostic and staging tool.
URPOSE OF THIS DOCUMENT
This document summarizes proposed measures
nd criteria for assessing outcomes in clinical trials
nvolving patients with chronic GVHD. The mea-
ures and criteria do not necessarily reﬂect practices
hat might apply to routine patient care or to trials
ith limited resources. The measures and response
riteria were developed to meet certain requirements.
. The instruments should be easy to use by both transplan-
tation and nontransplantation care providers and should
be limited to testing methods that are available in the
outpatient setting.
. The criteria should be adaptable for use in adults and in
children.
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2. The instrument should focus on the most important and
most common manifestations of chronic GVHD and
should not be designed to characterize all possible clinical
manifestations.
. Development should focus on quantitative measures as
much as possible.
. Measurements of symptoms, signs, global ratings, func-
tion, quality of life, or performance status should be
made separately, and scales with established psychometric
characteristics and desirable measurement properties
should be used whenever possible [10,11].
. With appropriate reﬁnements and reliability and vali-
dation assessments, these tools should be suitable for use
in clinical trials where the goals are to improve patient
outcomes or to obtain regulatory approval.
The Working Group had 3 additional goals: (1) to
ropose provisional deﬁnitions of complete response,
artial response, and disease progression for each or-
an and for overall response; (2) to suggest appropri-
te strategies for using short-term end points in ther-
peutic clinical trials; and (3) to outline future research
irections.
UMMARY OF RECOMMENDATIONS
. Proposed chronic GVHD-speciﬁc core measures
include:
A. Clinician- or patient-assessed signs and symp-
toms.
B. The chronic GVHD symptom scale by Lee
et al [12].
C. The clinician- or patient-reported global rating
scales (Table 1) [12-14].
To facilitate validation studies, continuous data
hould be recorded as such and should not be reduced
o prespeciﬁed categories.
. Proposed chronic GVHD nonspeciﬁc ancillary
measures for adults include:
A. Measurement of grip strength [15-17] and
2-minute walk time [18].
able 1. Proposed Measures for Assessing Responses in Chronic GVHD
Measure Clinician Assessed
. Chronic GVHD-specific core measures
Signs Organ-specific measures
Symptoms Clinician-assessed symptom
Global rating Mild-moderate-severe [12]
0-10 severity scale [13]
7-point change scale [14]
I. Chronic GVHD-nonspecific ancillary measures
Function Grip strength [15-17]
2-min walk time [18]
Performance status Karnofsky or Lansky [26]
Quality of life
SK indicates Activities Scale for Kids; GVHD, graft-versus-host d
Health Ratings Inventories.
54B. Patient-reported Human Activity Proﬁle (HAP)
questionnaire [19].
C. Clinician-assessed Karnofsky performance sta-
tus.
D. The SF-36 version 2 questionnaire [20,21] and
FACT-BMT for quality-of-life assessments
(Table 1) [22].
The ancillary chronic GVHD nonspeciﬁc mea-
ures are optional and should not be used as primary
nd points in chronic GVHD trials.
. Age-appropriate modiﬁcations of existing measures
should be used and explored in children with
chronic GVHD [23-29].
. Deﬁnition of response involves a comparison of
chronic GVHD activity at two different time
points. Provisional deﬁnitions of complete re-
sponse, partial response, and progression are of-
fered for each organ and for overall outcomes.
Simple forms to be used for clinician and patient
assessments are provided in Appendices A and B at
http://www.asbmt.org/GvHDForms (Forms A and
B). In each speciﬁc trial, irreversible baseline organ
damage may be deﬁned initially and then excluded
in response assessments.
. Measures should be made at 3-month intervals and
whenever a major change is made in treatment.
Permanent discontinuation of systemic immuno-
suppressive treatment indicates a durable response.
. Further assistance from subspecialists will be
needed to develop organ- or site-speciﬁc measures
that could improve the sensitivity of chronic
GVHD assessments. Speciﬁc organ or site assess-
ments discussed by the Working Group include the
following:
A. Skin: skin-speciﬁc scoring systems [30], durom-
eter [30-32], biopsy [31], or imaging (ultra-
sound, magnetic resonance imaging) [33,34].
B. Eyes: corneal staining grading [35], conjunc-
tival grading [36], ocular surface disease
index [37].
Patient Reported
N/A
Patient-reported symptoms Lee symptom scale [12]
Mild-moderate-severe [12]
0-10 severity scale [13]
7-point change scale [14]
HAP [19]
ASK in children [23-25]
SF-36v.2 [20,21] or
FACT-BMT [22] in adults
CHRIs in children [27-29]
N/A, not applicable; HAP, Human Activity Proﬁle; CHRIS, ChildTrials
s
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Response Criteria in Chronic GVDH
BC. Oral: Oral Mucositis Rating Scale [38].
D. Vulvar-vaginal: organ-speciﬁc staging [39,40].
E. Function: range of motion, limb volume, fa-
tigue severity scale [41-43].
ROPOSED MEASURES OF CHRONIC GVHD
ESPONSE ASSESSMENTS
The Working Group distinguished between
hronic GVHD-speciﬁc core measures that directly
easure organ-speciﬁc manifestations of chronic
VHD and nonspeciﬁc ancillary measures, which
ould reﬂect the overall impact of chronic GVHD and
ther illness on functioning or quality of life (Table 1).
n future studies, these measures should be evaluated
or construct validity (for Glossary see Attachment 2
t: http://www.asbmt.org/GvHDForms) and potential
tem reduction. In a feasibility study, 8 clinicians who
ad never previously used the assessment forms eval-
ated 4 adults with chronic GVHD [44]. The median
ime for each clinician evaluation was 36 minutes, and
he median time needed to complete the panel of
atient self-report items was 14 minutes. Results of
his evaluation offered preliminary evidence of reli-
bility, feasibility, and acceptability of the newly pro-
osed measures.
able 2. Proposed Clinician-Assessed and Patient-Reported Chronic GV
Component Items A
kin Erythematous rash of a
Movable sclerosis
Nonmoveable sclerosis
sclerosis/fasciitis
Ulcers
Pruritus or itching
yes Bilateral Schirmer’s te
anesthesia
Main ocular symptom
outh Erythema
Lichen-type hyperkera
Ulcerations
Mucoceles
Symptoms of oral pain
ematology Platelet count
Eosinophils
I Upper GI symptoms
Esophageal symptoms
Diarrhea
iver Total serum bilirubin
ALT, alkaline phosphat
ungs Bronchiolitis obliterans
hronic GVHD symptom scale [12] 30 items, 7 subscales, 1
lobal activity rating Severity of chronic GV
Perception of change
Overall severity of chr
LT indicate alanine aminotransferase; C, assessed by the clinici
expiratory volume in the ﬁrst second; GI, gastrointestinal; GVH
ulvar-vaginal symptoms (yes or no) and patient weight should be
ange of motion of the most affected joints should be recorded dependin
B&MTROPOSED CLINICIAN-ASSESSED
ND PATIENT-REPORTED CHRONIC
VHD-SPECIFIC MEASURES
The following sections describe the recommended
linician-assessed and patient-reported chronic GVHD-
peciﬁc measures (Table 2). Speciﬁc pediatric consid-
rations for such situations are highlighted where ap-
ropriate. For the assessment of symptoms in younger
hildren, depending on the child’s development, assis-
ance can be provided by the health care provider or
he parent. The Working Group also recommends
ormal in-person training for all assessments to min-
mize intraobserver and interobserver variability.
nstructional manual and slide set to assist with
uch training are available at http://www.asbmt.org/
vHDForms.
rgan-specific Assessments
Skin and skin appendages. Skin is the most fre-
uently affected organ in chronic GVHD, and mani-
estations are highly variable. Skin assessments are
tructured to reﬂect 4 anatomic levels of skin involve-
ent: (1) erythematous rash (epidermal involvement);
2) movable sclerosis (dermal involvement); (3) non-
oveable sclerosis, hidebound skin, or involvement of
eciﬁc Measures
d Measure Assessor
t % Body surface area C
0%-100% For each feature C
cutaneous By using rule of nines C
Largest dimension (cm) of
the largest ulcer
C
0-10 Scale P
scores without Mean of both eyes, mm C
time of the visit 0-10 Scale P
Total score 0-15 C
C
C
C
ss, sensitivity 0-10 Scale P
Number/L C
Percent C
0-3 Score C
0-3 Score C
0-3 Score C
mg/dL C
U/L C
ome FEV1, DLCO C
ary scale 0-100 P
ptoms 0-10 C/P
3 to 3 C/P
HD Mild – moderate-severe C/P
CO, diffusion lung capacity for carbon monoxide; FEV1, forced
aft-versus-host disease; P, reported by the patient.
ed at each visit.HD-Sp
ssesse
ny sor
or sub
ar test
at the
tosis
, dryne
ase
syndr
summ
HD sym
onic GV
an; DL
D, gr
recordg on the availability of a physical therapist.
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2ubcutaneous tissue and fascia (subcutaneous involve-
ent); and (4) ulceration (full thickness loss of epider-
al tissue) (Figure 1). Abnormalities for the ﬁrst 3
oints are each assessed separately according to the
ercent of body surface area (BSA) involved as esti-
ated by the rule of nines for adults. A worksheet for
ecording the BSA involved for each of 8 skin regions
s provided at: http://www.asbmt.org/GvHDForms
Attachment 3). Ulcer size is assessed by measuring
he largest diameter of the largest ulcer.
The term “erythematous rash of any sort” is used
s an inclusive reference to the many superﬁcial skin
ruptions of chronic cutaneous GVHD including
apular, lichen planus-like, papulosquamous, poikilo-
erma, and keratosis pilaris-like rashes. The term “li-
henoid” is not used, because this is a histopathologic
iagnosis, not a clinical descriptive term.
Likewise, the term “sclerosis” or “sclerotic” is used
o represent the general category of cutaneous GVHD
ndings associated with skin ﬁbrosis, and to avoid
onfusion with the autoimmune disorder scleroderma.
uperﬁcial sclerosis (moveable) includes both lichen
clerosus-like and morphea-like lesions. Deep sclero-
is includes diffuse, immovable (hidebound) sclerosis
nvolving a wide area of skin, ﬁbrosis of subcutaneous
at septae (rippling), and fasciitis (groove sign). Scle-
igure 1. Skin manifestations assessed for response in chronic GVH
mall scaly plaques. C, Dermal sclerosis. Skin is thickened, with dec
, Subcutaneous sclerosis. Skin is hidebound, ﬁxed to underlying totic skin manifestations may be as variable as the G
56uperﬁcial form of the disease and are difﬁcult to
easure reliably. Sclerotic changes respond slowly to
herapy and progression or regression of sclerotic le-
ions ideally should be assessed not only according to
he total surface area involved but also according to
he depth of involvement at any given site.
Because quantitative methods to measure the depth
f sclerotic involvement are not available in a general
ncology practice, these changes have been described in
ore qualitative terms related to thickening, pliability,
dherence to underlying tissues, or changes in joint mo-
ility. No validated scale exists for assessing sclerotic skin
hanges of chronic GVHD. Measures such as the Rod-
an score for assessment of systemic sclerosis might be
elpful for clinical evaluation of chronic GVHD, but this
cale does not measure lichen sclerosus-like changes,
ubcutaneous involvement without overlying skin thick-
ning, or fascial involvement. For this reason, the Rod-
an score is not suitable for use in clinical trials. More
ophisticated skin-speciﬁc scores are being developed for
se by trained assessors in selected clinical trials (R.
nobler, MD, and H. Greinix, MD, oral communica-
ion, December 2005). There is an urgent need for the
evelopment of more quantiﬁable and reproducible
easurements or imaging methods that could be used in
atients with sclerotic skin manifestations of chronic
Erythematous papular rash. B, Erythematous rash with papules and
mobility to pinching but without adherence to underlying tissues.
and cannot be pinched. Ulcers are present.D. A,
reasedVHD [30-34].
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Response Criteria in Chronic GVDH
BPigmentary changes do not indicate activity in
hronic GVHD disease per se. Moreover, changes in
igmentation occur gradually and are perceptible only
cross long time intervals. Nonetheless, these changes
hould be recorded in the assessment forms, as de-
cribed in the Diagnosis and Staging document [9],
ecause they indicate the extent of previous skin
nvolvement. Individuals who assess chronic GVHD
f the skin should consult a picture atlas that is
vailable for training and standardization (http://
ww.asbmt.org/GvHDForms).
The patient symptom intensity self-report proﬁle
ncludes the most severe itching during the past week,
ated according to a 1-to-10 scale, because itching is the
ost frequent cutaneous symptom of chronic GVHD.
The rule of nines as an estimate of BSA involve-
ent is intended for use in adults and is less accurate
n children, particularly young children. For the sake
f simplicity, we recommend using the rule of nines
or all children, except for those younger than 1 year.
BSA grid for children younger than 1 year can be
ound at: http://www.asbmt.org/GvHDForms (At-
achment 4).
Eyes. Dry eyes reﬂect either lacrimal dysfunction
r destruction. The primary measure of lacrimal gland
unction in chronic GVHD is the Schirmer’s test (to
e performed without anesthesia) for each eye sepa-
ately, as recommended by the Sjögren’s syndrome
onsensus group [45]. Objective improvement would
ot be expected in cases where dry eyes and abnormal
chirmer’s test result from complete lacrimal destruc-
ion. Instructions for administration of the Schirmer’s
est are provided with the instructional manual at:
ttp://www.asbmt.org/GvHDForms.
The patient symptom intensity self-report proﬁle
ncludes the chief eye complaint rated according to a
-to-10 scale for peak severity during the past week.
he complaint can change from visit to visit, but only
ne chief eye complaint is graded. This method is
imple to use but may impose undesirable limitations
n patients with multiple complaints. In addition, oc-
lar symptoms in patients with chronic GVHD can
ave causes other than chronic GHVD.
Schirmer’s test without anesthesia is not recom-
ended for children younger than 9 years, and eval-
ation by an ophthalmologist may be needed for ob-
ective scoring in younger children.
Mouth. Mouth assessments are conducted by using
he newly proposed modiﬁcation of the Schubert Oral
ucositis Rating Scale that scores oral surfaces from 0
o 15, with higher scores indicating more severe in-
olvement. The 4 chronic GVHD manifestations as-
essed in this scale include: (1) mucosal erythema (0-3)
rading based on the color intensity; (2) lichen-type
yperkeratosis (percent of oral surface area); (3) ulcer-
tions (percent of oral surface area); and (4) presence
f mucoceles (total number) (Figure 2). Instructions r
B&MTor these assessments and a photo dictionary are pro-
ided in the instructional manual on the World Wide
eb: http://www.asbmt.org/GvHDForms.
The patient self-report symptom intensity proﬁle
ncludes dry mouth (subjective decrease in oral wet-
ess), mouth pain in the absence of stimulation, and
outh sensitivity (irritation resulting form normally
olerated spices, foods, liquids, or ﬂavors), each rated
ccording to a 1-to-10 scale for peak severity during
he past week.
Hematopoietic. Parameters to be evaluated for re-
ponse assessments are absolute platelet count [46]
nd absolute eosinophil count [47]. Total white count
nd percent eosinophils are also recorded on the form
t the time of the clinic visit.
Gastrointestinal tract. Gastrointestinal (GI) symp-
oms are difﬁcult to measure in the outpatient setting.
or this reason, GI symptoms during the preceding
eek are graded not through patient self-report forms
ut through interview by the examining clinician ac-
ording to 0-to-3 severity scales. For upper GI symp-
oms of early satiety, anorexia, nausea, and vomiting, a
core of 1 indicates mild, occasional symptoms, with
ittle reduction in oral intake. A score of 2 indicates
oderate, intermittent symptoms, with some reduc-
ion in oral intake, and a score of 3 indicates more
evere or persistent symptoms throughout the day,
ith marked reduction in oral intake on most days.
or esophageal symptoms of dysphagia or odynopha-
ia, a score of 1 indicates occasionally difﬁcult or
ainful swallowing of solid foods or pills. A score of 2
ndicates intermittent dysphagia or odynophagia with
olid foods and pills, but not for liquids or soft foods,
nd a score of 3 indicates dysphagia or odynophagia
or almost all oral intakes on most days. Finally, for
ower GI symptoms, a score of 1 indicates occasional
oose or liquid stools, on some days. A score of 2
ndicates intermittent loose or liquid stools through-
ut the day without requiring intervention to prevent
r correct volume depletion, and a score of 3 indicates
oluminous diarrhea requiring intervention to prevent
r correct volume depletion.
Patients with chronic GVHD often have weight
oss that is not always explained by GI symptoms [48].
lthough the exact relationship between weight loss
nd chronic GVHD activity is not clear, patient
eight should be recorded at each scheduled evalua-
ion, given the simplicity of this measure and its po-
ential importance for monitoring the success of ther-
py.
Liver. Liver injury should be assessed according to
he most recent laboratory results for total serum
ilirubin (mg/dL), alanine aminotransferase (U/L),
nd alkaline phosphatase (U/L). Laboratory upper
imits of normal should also be recorded.
Lung. Measures that can be used to evaluate the
esponse of bronchiolitis obliterans syndrome (BOS)
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2fter therapy are forced expiratory volume in the ﬁrst
econd (FEV1) and single breath diffusion lung capac-
ty for carbon monoxide (DLCO) adjusted for hemo-
lobin, both of which are included in standard pulmo-
ary function testing [49]. These two parameters are
lso included as components of the lung function
core (LFS) that was recently developed as a predictor
f respiratory failure and mortality after allogeneic
ematopoietic stem cell transplantation [50]. A mod-
ﬁed LFS is proposed as a simple measure of changes
n the lung function in patients with BOS (see Table
). Pulmonary function tests should be performed in
hildren who are older than 5 years.
The LFS is computed according to FEV1 and DLCO
easurements compromise (80% of predicted  1,
0%-79%  2, 60%-69%  3, 50%-59%  4, 40%-
9% 5,40% 6). The scores for FEV1 and DLCO
re then added together, and the sum is reduced to an
verall category according to Table 3.
It is important to emphasize that the LFS has
ever been used in chronic GVHD response assess-
igure 2. Oral manifestations assessed for response in chronic GV
rythema. B, Area of sheetlike lichenoid hyperkeratosis is presen
urrounded by severe erythema. D, Numerous vesicle-like mucocele
nd moderate erythematous changes.ents, and its exact role in this setting needs to be
58etermined. To allow validation in trials, absolute
alues of both FEV1 and DLCO should be recorded
n the data collection forms.
Vulva and vagina. Women should be asked speciﬁc
uestions relating to vulvar and vaginal symptoms,
uch as burning, pain, discomfort, or dyspareunia.
atients who report problems should be referred to a
ynecologist. Because such symptoms could be caused
y conditions other than chronic GVHD, and because
roper evaluation requires a specialist examination,
his information should be recorded but not scored for
esponse assessment. Academic gynecologists inter-
sted in chronic GVHD are developing precise vul-
ovaginal assessment scales. These scales will be useful
able 3. Categories of the Lung Function Score
Category Lung Function LFS
I Normal 2
II Mild decrease 3-5
III Moderate decrease 6-9
, Moderate erythema of vermilion lip. Labial mucosa shows severe
commissure. C, Ulcer with pseudomembranous ﬁbrin exudates
en at center of the palate, with patches of lichenoid hyperkeratosisHD. A
t inside
s are seIV Severe decrease 10-12
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Bn selected trials where vulvar and vaginal changes are
he primary end points of interest [39,40].
Musculoskeletal connective tissue. Active-assisted
ange of joint motion could potentially serve as a very
seful objective measure of chronic GVHD tissue
esponse in patients with sclerotic changes involving
arge joints or the trunk. The main limitation of this
ool, however, is the need for an adequately trained
rofessional (usually a physical therapist) who can
onduct the range-of-motion measurements in a stan-
ardized and reproducible fashion. If such a trained
rofessional is available, pertinent range-of-motion
easurements should be recorded sequentially, and
or this purpose, trained clinicians should also be able
o make serial measurements of selected sentinel joints
or routine assessment purposes. Normal levels are
vailable for adults and for children [51].
hronic GVHD Symptoms
Lee et al [12] developed a symptom scale designed
or individuals with chronic GVHD. The question-
aire asks respondents to indicate the degree of bother
hat they experienced during the past 4 weeks as a
esult of symptoms in 7 domains potentially affected
y chronic GVHD (skin, eyes and mouth, breathing,
ating and digestion, muscles and joints, energy, emo-
ional distress). Published evidence supports its valid-
ty, reliability, and sensitivity to chronic GVHD se-
erity. Items in this symptom scale can be reported in
pproximately 5 minutes.
The Lee chronic GVHD symptom scale has been
ested only in individuals older than 18 years. Given
ts face validity and other desirable properties, how-
ver, this scale could be used for assessment of chronic
VHD in pediatric patients using either child or
arent report, after appropriate modiﬁcation and psy-
hometric evaluation [52]. Information for the chronic
VHD symptom scale could be obtained by self-
eport from adolescents older than 12 years. For chil-
ren who are 8 to 12 years of age, data should be
btained with the assistance of parents and the health
are provider.
The Lee scale measures symptom bother as dis-
inguished from symptom intensity, which is reported
n the forms in Appendix B [53]. The degree to which
atients report that they are bothered by a symptom
epresents a global assessment incorporating not only
he intensity of the symptom and its frequency, but
lso the degree to which it causes emotional distur-
ance or interferes with functioning. The Lee scale
omplements the information regarding the intensity
f chronic GVHD symptoms. For example, oral sen-
itivity may be severe, but patients may report that
hey are not bothered or distressed by this symptom.
y contrast, skin itching may not be very intense or
requent but may cause great distress. Research is a
B&MTeeded to determine the relationships between symp-
om intensity, frequency, and distress or bother in
atients with chronic GVHD and to examine the
egree to which these are distinct dimensions of the
ymptom experience.
linician- and Patient-Reported Global Ratings
Clinician perceptions. Physicians, nurse practitio-
ers, or physician assistants should provide an assess-
ent of current overall chronic GVHD severity on a
-point scale (none, mild, moderate, severe) [12] and
hey can also provide an assessment of current overall
hronic GVHD severity on an 11-point numeric scale
0 indicates no GVHD manifestations; 10 indicates
ost severe chronic GVHD symptoms possible). The
ategories of mild, moderate, and severe have been
sed in previous studies for patient and clinician as-
essment, where they were undeﬁned but showed
ood prognostic characteristics [12,54]. Clinicians
hould also provide their assessments of patient
hronic GVHD changes during the past month scored
n a 7-point scale (very much better, moderately bet-
er, a little better, about the same, a little worse,
oderately worse, very much worse) [14].
Patient perceptions. Similarly, at each patient self-
ssessment, patients should score their perceptions of
verall chronic GVHD severity, overall severity of
ymptoms, and change in symptom severity compared
ith 1 month ago, using the same response options
sed by clinicians.
The exact role of global scales in chronic GVHD
esponse assessments and their appropriate use as out-
ome measures in clinical trials remains to be deter-
ined. These scales could be sensitive to qualitative
hanges that might otherwise escape detection if the
ssessments were limited to quantitative measures.
ROPOSED CHRONIC GVHD NONSPECIFIC MEASURES
Nonspeciﬁc measures of function and patient-re-
orted outcomes related to functional status and
ealth-related quality of life could potentially offer
dditive objective and subjective data regarding the
ffects of chronic GVHD and its therapy. The
VHD nonspeciﬁc measures listed for consideration
n Table 1 assess different dimensions of the patient
xperience. Selection of these instruments was based
n the credibility and relevancy of their measurement
roperties (reliability, validity, responsiveness) and the
vailability of normative data to facilitate interpreta-
ion. Instruments that use self-report methods as op-
osed to interview-assisted reporting will promote
easibility in clinical trials, and the number of instru-
ents was circumscribed to limit the burden on re-
pondents. Consideration was also given to the avail-
bility of detailed instructions, procedure manuals,
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2oding algorithms and scoring systems, and back-
round information regarding the conceptual and
easurement properties of the instrument. The po-
ential role of these nonspeciﬁc measures as outcomes
n chronic GVHD therapeutic clinical trials needs to
e determined in future research.
unctional Status
For an extremely complex multisystem disease
uch as chronic GVHD, objective measures of physi-
al performance and patient-reported measures of
unctional status could represent important surrogate
utcomes that might be more informative than the
easures described above for assessing outcome in
ome situations (eg, advanced skin sclerosis). At the
ery least, measures of functional status can provide
orroborative evidence of important changes after
herapy. In other patient populations with chronic
iseases [55-57], such outcomes have been extensively
pplied, and population norms for both physical per-
ormance measures and self-reported functional status
re available. Because the use of functional end points
n chronic GVHD assessment has not been exten-
ively tested, and because these measures do not di-
ectly assess chronic GVHD manifestations, func-
ional status outcomes can be used only as optional
econdary end points in chronic GVHD trials until
urther information in available.
Proposed objective measures of physical perfor-
ance include grip strength [15-17] measured using
hydraulic dynamometer (measured in pounds of
ressure) and the 2-minute walk distance (measured
s total distance in feet walked in 2 minutes) [18].
lthough the measurement properties for the
-minute walk distance have been less thoroughly
xamined than those of the 6-minute walk distance,
he 2-minute walk may be a more feasible and efﬁ-
ient measure of performance in patients with
hronic GVHD. Studies support the construct va-
idity and responsiveness to change characteristics
f the 2-minute walk distance [58,59]. Age-matched
orms for walk time and grip strength are available for
dults and for children. These simple instruments
ight not be available in the typical oncology clinic,
ut they can be obtained from rehabilitation med-
cine departments or purchased (eg, at: http://www.
ehaboutlet.com/grip_hand_dynamometer.htm).
HAP. Recommended patient-reported measures
f functional status include the HAP questionnaire
for adults) and the Activities Scale for Kids question-
aire (for children age 5-15 years) [19,23-25]. The
AP is a measure of physical activity. The 94 ques-
ions are ranked hierarchically in ascending order ac-
ording to the metabolic equivalents of oxygen con-
umption required to perform each activity [19]. The
AP, therefore, provides a survey of the activities the G
60atient performs independently across a wide range of
etabolic demand, beginning with getting out of bed,
athing, dressing, walking using public transit, per-
orming a series of progressively more physically de-
anding household chores, and ending with running
r jogging 3 miles in 30 minutes or less. The recom-
ended corollary instrument to measure self-reported
unction in children is the Activities Scale for Kids
23-25].
Performance scales. The Karnofsky Performance
cale is commonly used in clinical assessments of
hronic GVHD and has prognostic value for survival
60]. Whether a clinician assessment that combines
erformance, health status, and impairment is a valid,
eliable, or sensitive tool to gauge response after ther-
py for chronic GVHD remains to be determined.
erformance scores should nonetheless be recorded as
art of each assessment. Lansky Play Performance
cale scores should be recorded for children younger
han 16 years [26].
elf-Reported Health-Related Quality of Life
The effects of chronic GVHD and its treatment
n general physical and emotional health and quality
f life are other patient-reported outcomes that may
e responsive to change as a result of chronic GVHD
herapy [61]. The Medical Outcomes Study Short
orm 36-item Questionnaire version 2* is a measure
hat has had wide application and is well accepted as
easure of self-reported general health and the de-
ree to which health impairments interfere with ac-
ivities of daily living and role function [21,62]. The
unctional Assessment of Chronic Illness Therapy is
n oncology-speciﬁc quality-of-life instrument that
as well-developed psychometric properties, and pop-
lation norms for healthy individuals and those with
oth mild and more severe chronic illnesses. An ad-
itional 18-item disease-speciﬁc module evaluates
oncerns common to patients who have had stem cell
ransplantation (FACT-BMT)* [22]. These instru-
ents are appropriate for patients older than 18 years.
n pediatric patients, the Child Health Ratings Inven-
ories* generic core and Disease-Speciﬁc Impairment
nventory-HSCT*, a hematopoietic cell transplanta-
ion-speciﬁc module, could serve as a surrogate for
ACT-BMT [27-29].
Cross-sectional studies have shown that chronic
VHD has an adverse effect on quality of life [63], but
he role of quality of life as a measure of response to
herapy or as a predictor of long-term outcome re-
ains to be deﬁned. Patient-reported quality-of-life
easures cannot replace quantitative measures of
hronic GVHD activity in clinical trials. Patient-re-
orted items should be selected to address speciﬁc
uestions and should have relevance for chronic
VHD. Each instrument should be considered not
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Bnly for the information that it might provide in its
wn right but also for the information that it might
dd in the context of other instruments to be used in
ssessments. Hence, investigators should be aware of
imilarities and differences between instruments when
aking decisions about their use in clinical trials.
nvestigators should take care not to impose an exces-
ive burden of self-report items on those who are
articipating in clinical trials. A table comparing
bove-discussed chronic GVHD-speciﬁc and the op-
ional patient-reported nonspeciﬁc measures is pro-
ided at: http://www.asbmt.org/GvHDForms (At-
achment 5). The recommendation to use these
nstruments does not imply permission for their use in
linical trials. Investigators should follow the proce-
ure established by the organizations that hold copy-
ight for each instrument (see Attachment 5).
HRONIC GVHD DATA COLLECTION FORMS
Appendices A and B (http://www.asbmt.org/
vHDForms [Forms A and B]) show data collection
orms for the recommended clinician-assessed and pa-
ient-reported measures. In clinical trials, data should
e submitted to the study coordinating center for
urther calculations, processing, and interpretation of
esponses. It is not necessary to include recommended
easures in every trial, and judgment must be used in
eciding which items will best suit the needs of each
tudy. In all studies, the measures to be made and the
iming of the measures must be speciﬁed.
ROVISIONAL CRITERIA FOR DEFINITION
F RESPONSE
Protocols must specify the times when response
ill be assessed, and the requirement for durability of
esponse (see forthcoming Design of Clinical Trials
orking Group report). Permanent discontinuation
f systemic immunosuppressive treatment indicates a
urable response.
Certain changes such as dry eyes, esophageal stric-
ure, bronchiolitis obliterans, or advanced sclerotic
kin lesions may be considered irreversible and may be
xcluded from consideration for assessments of com-
lete or partial response, if speciﬁed by the protocol.
To assess response, disease manifestations at two
ifferent time points must be compared, and a judg-
ent must be made as to whether the magnitude of
ny change qualiﬁes as clinical improvement or clini-
al deterioration. The magnitude of change required
or clinical improvement or deterioration should re-
ect genuine clinical meaning, and the criteria should
e developed and standardized as much as possible.
his standardization may be relatively easy to estab-ish for manifestations that can be measured quantita- t
B&MTively with little day-to-day variation but will be more
ifﬁcult to establish for manifestations that can be
easured only in more qualitative ways.
The statistician should be always be included early
n the development of the trial design and should help
o select the analyses that best ﬁt the types of measures
eing collected. Because no criteria for deﬁning
eaningful improvement or clinical beneﬁt have been
alidated for measures of chronic GVHD, the results
f trials should include both the categorical outcomes
eﬁned below and the average change from baseline
or each parametric measure. Protocols should specify
hether change is to be calculated according to per-
ent of full scale or percent of baseline. Analysis of
ercent changes is particularly needed for the inter-
retation of smaller early drug-development trials.
Pending appropriate validation studies, the Work-
ng Group proposes the following consensus deﬁni-
ions of complete response, partial response, and
rogression. The complete and partial response cate-
ories apply only to organs that have measurable and
eversible GVHD-related abnormalities at baseline.
or certain organs and measures, however, chronic
VHD sequelae can reﬂect damage that is not revers-
ble. Some obvious examples of this problem are
hronic dry eyes, esophageal stricture, bronchiolitis
bliterans, or advanced skin sclerosis or contractures.
or these manifestations, the category of complete
rgan response may not apply if protocols prespecify
ny such exclusion. The progression category applies
o all organs.
bjective Measures of GVHD Activity
Complete organ response. The term “complete organ
esponse” indicates resolution of all reversible mani-
estations related to chronic GVHD in a speciﬁc organ.
Partial organ response. The proposed general
uideline for deﬁning partial response in speciﬁc or-
an requires at least 50% improvement in the scale
sed to measure disease manifestations related to
hronic GVHD. This guideline was selected as un-
quivocally indicating genuine clinical beneﬁt. The
riterion of 50% improvement requires some adjust-
ent in cases where the extent of abnormality at the
aseline measurement is low. For example, there
ould be no question that a 50% decrease in rash
rom 80% of BSA to 40% represents genuine clinical
mprovement. On the other hand, the same 50% de-
rease from 5% of BSA to 2.5% would represent a
uch less compelling clinical improvement. For this
eason, when the extent of abnormality at the baseline
easurement is lower than the midpoint on the scale,
he minimum criterion for response should be deﬁned
s percentage (eg, 25%) of the full scale as opposed to
percentage of the starting value. To be consistent, ifhe extent of abnormality at the baseline measurement
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2s lower than the minimum percent of full-scale
hange needed to deﬁne a partial response (eg, 25% of
he full scale), then the only possible response would
e a complete response.
Organ progression. Criteria for progression in each
rgan must be deﬁned, because the overall category of
artial response requires the absence of progression in
ny organ (see below). For an organ affected by
hronic GVHD at the baseline evaluation, the pro-
osed general guideline for deﬁning progression spec-
ﬁes an absolute increase of at least 25% in the scale
sed to measure disease manifestations related to
hronic GVHD. Progression cannot be scored for
anifestations with baseline values that are within
5% of the full-scale value. When baseline measures
f chronic GVHD severity are 50% to 75% of full
cale at baseline, the criteria for improvement require
ore than a 50% change from baseline (which pro-
uces more than a 25% of full-scale change), whereas
25% of full-scale change is sufﬁcient for progression.
his asymmetry in the minimal criteria for improve-
ent and progression is intended to ensure a high
evel of conﬁdence that any improvement is clinically
eaningful and to ensure early detection of any
eterioration.
Proposed guidelines for calculating partial re-
ponse and progression and instructions for use by
tudy coordinating centers are available on the World
ide Web at: http://www.asbmt.org/GvHDForms.
tm (Appendices C and D). The criteria proposed in
hese guidelines are admittedly arbitrary, because in
ost cases, they have never been validated for patients
ith chronic GVHD, and the distribution of baseline
cores is unknown. For these reasons, the proposed
riteria are provisional and subject to change with
urther clinical experience. Also, depending on the
tringency of response deﬁnitions required by the spe-
iﬁc study, these general guidelines could be modiﬁed
o ﬁt the needs of a particular protocol. Because the
riteria are subject to change, we strongly recommend
hat data report forms should always record the actual
umeric values for any measurement.
Limitations in measurement of organ responses. The
esponse criteria in Appendix C do not account for
ualitative changes. Clinical experience indicates that
linically important qualitative improvement often oc-
urs before improvement in the measures summarized
n Appendix C. For this reason, the response criteria
n Appendix C should not be used as the primary
uide for clinical decisions. Certain organs are not
onsidered in Appendix C because quantitative assess-
ents are not feasible. The response criteria also do
ot account for the prior trajectory of abnormalities.
or example, stable disease might be considered a
esponse when the prior trajectory was clear progres-
ion, as indicated, for example, by serial pulmonary
unction tests. Stable disease after prior improvement g
62ould not be considered a favorable outcome, and
table disease after prior stability cannot be considered
response.
Standardized response criteria for BOS associated
ith chronic GVHD have never been investigated.
he hallmark of response to therapy for BOS is sta-
ilization of lung function with no further decrease in
EV1 during a 3-month period. A few cases of im-
roved FEV1 after therapy for BOS have been re-
orted, but these outcomes could reﬂect disease mis-
lassiﬁcation or very early treatment.
Deﬁnitions of overall response. Three general overall
ategories of response are proposed: complete re-
ponse, partial response, and other. Although the
roup recognizes the complete and partial responses
s the categories of greatest interest, other summary
utcomes such as stable disease or mixed response can
e also included in clinical trials. Complete overall
esponse is deﬁned as resolution of all reversible man-
festations in each organ or site, and partial overall
esponse is deﬁned as improvement in a measure for at
east one organ or site without progression in mea-
ures for any other organ or site. We do not propose
he routine use of the term “stable disease” because
he interpretation depends too heavily on the prior
rajectory of the disease, as discussed above.
lobal Ratings, Patient-Reported Outcomes,
nd Performance Measures
The terms “complete response,” “partial re-
ponse,” and “progression” do not technically apply to
ubjective or functional measures data. Instead, the
eﬁnition of improvement or worsening for such
cales is based on the reliability of the measure (the
ariability caused by measurement error) and is an-
hored against clinically perceptible changes. For
lobal ratings and categorical scales, a 1-point change
n a 3- or 7-point scale or a 2- to 3-point change (0.5
D change) on a 0- to 10-point scale could be con-
idered clinically meaningful, pending further evalua-
ion in the chronic GVHD population. Unless oth-
rwise speciﬁed, for all patient-reported measures, a
hange of 0.5 SD may be considered clinically
eaningful [64,65]. A distribution-based analysis
as used to deﬁne improvement as a change of 6 to
points (0.5 SD) on the chronic GVHD symptom
ummary scale [12].
Impairments of grip strength, walk time, and
ange of motion are measured by comparison with
ormative values. Minimal clinically meaningful im-
rovements for these measures are provisionally de-
ned as a 25% decrease in the level of impairment as
ompared with baseline. For HAP, clinically meaning-
ul improvement is deﬁned as a 10-point increase in
he maximum activity score, because a change of this
agnitude is sufﬁcient to change the disability cate-
ory at the middle of the scale.
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Response Criteria in Chronic GVDH
BSE OF RESPONSE ASSESSMENT AS A PRIMARY
ND POINT IN CLINICAL TRIALS
Beyond providing tools for assessment of re-
ponse, clinical protocols must select appropriate pri-
ary and secondary end points. A primary end point
epresents the principal basis by which the success or
ailure of a treatment will be decided, whereas second-
ry end points are selected to be supportive of the
rimary end point or to demonstrate that the beneﬁt
rovided with respect to the primary end point is not
ffset by a detrimental effect on other disease mani-
estations. Prespeciﬁed expectations regarding effects
f a study intervention on the primary end point also
rovide the basis for statistical power calculations used
o determine the number of patients to be enrolled. If
trial is going to be used for the marketing approval
f therapy, regulatory authorities should be included
arly in the planning.
Table 4 summarizes the potential use of organ
easures as primary end points in chronic GVHD
linical trials. Any of the listed assessments could be
sed as a secondary end point, with or without blind-
ng, but the validity of subjective assessments in open-
abel trials will always be open to question. The list of
ssessments in this table is limited to measurements
nd scales that could be used by a general internist or
ediatrician or by patients. More sophisticated assess-
ents of certain organs such as skin, eyes, mouth,
emale genital tract, and joints may be needed for
ertain studies [30-40]. Specialized expertise will be
eeded for these assessments, and the criteria for mea-
urement of response in these situations exceed the
cope of the current proposal.
Some of the response scales in Table 4 measure
linical beneﬁt, whereas others measure potential clin-
cal beneﬁt as reﬂected by a surrogate end point. For
xample, in cardiovascular disease, well-established
urrogate end points such as blood pressure or serum
holesterol can be used for regulatory approval. Less
ell-established surrogate end points could be used in
ertain circumstances if they are reasonably likely to
redict clinical beneﬁt. Elevated serum bilirubin levels
t the onset of chronic GVHD have been associated
ith an increased risk of nonrelapse mortality [1], but
alidation studies have not been carried out to show
hat improvement in serum bilirubin levels is associ-
ted with prolonged survival among patients with
hronic GVHD. Evaluation of other liver function
ests in patients with chronic GVHD has also not been
eported. For this reason, the acceptability of im-
roved liver function tests as a basis for approval
emains uncertain at this time.
Some of the response scales in Table 4 involve
bjective assessments, whereas others involve subjec-
ive assessments. Blinding of treatment arms to pre-
ent bias is recommended whenever feasible, espe- t
B&MTially when a subjective end point is used as a primary
nd point in a clinical trial. Even for objective assess-
ents, blinding can be extremely helpful in prevent-
ng bias. For example, objective assessments of the
kin and mouth can be enhanced through review of
erial photographs by a panel of individuals as blinded
ssessors who have no other information about the
atient. A similar approach could also be used in the
valuation of chronic GVHD involving the eye and
emale genital tract.
UTURE DIRECTIONS
The proposed response criteria are expected to
nhance uniformity of data collection methods and
dvance standards of chronic GVHD clinical trials but
re only provisional and it is imperative that they be
ested for reliability and validity in prospective studies.
mportant tasks for the immediate future include the
etermination of minimal clinically important changes
or some of the measures proposed, determination of
ost relevant measures, reduction of items, and estab-
ishing an outcomes repository for data collected in
linical trials and natural history studies using these
nstruments. Collaborations with organ-site specialist
hould be strengthened to develop methods for more
ensitive and objective assessment of speciﬁc organs.
uture studies will be needed to determine the extent
able 4. Potential Use of Chronic GVHD-speciﬁc Measures as
rimary End Points in Clinical Trials
Organ and Assessment Clinical Benefit Blinding Required
kin
Objective assessment Yes No*
Pruritus Yes Yes
yes
Schirmer’s tear test Yes No
Ocular discomfort Yes Yes
outh
Objective assessment Yes No*
Oral pain Yes Yes
Oral dryness Yes Yes
Oral sensitivity Yes Yes
ematology Unknown No
astrointestinal symptoms Yes Yes
iver
Bilirubin Unknown No
Alkaline phosphatase Unknown No
Aminotransferase levels Unknown No
ungs Yes No
ymptom scale Yes Yes
lobal rating scales Yes Yes
ange of motion Yes No*
VHD indicates graft-versus-host disease.
his table is limited to consideration of possible primary end points.
Any of the listed assessments could be used as a secondary end
point, with or without blinding.
Objective assessments could be enhanced with the use of photo-
graphs and/or blinded assessor.o which patient-reported outcomes and functional
263
m
c
b
t
c
h
N
D
T
C
L
S
e
S
F
M
e
W
c
b
a
t
A
i
c
D
t
N
i
A
t
O
P
f
I
O
N
T
R
T
C
M
T
l
t
e
f
s
N
G
T
p
S
z
i
O
s
o
a
m
t
e
L
O
M
h
R
A
R
P
R
t
R
P
R
o
D
R
R
W
R
d
R
c
E
R
S. Pavletic et al.
2easures could be used as a primary end point in
hronic GVHD clinical trials. Improved methods will
e needed to distinguish chronic GVHD disease ac-
ivity from irreversible damage and to develop a
hronic GVHD activity index for clinical trials, per-
aps through the use of biomarkers [66].
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